Earnings Releases·Nov 9, 2026, 8:07 AM ET

Quanterix — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached $35.0 million (up 6.3% sequentially), while the nine-month total rose to $104.3 million (up from $95.0 million in 2025); GAAP net loss narrowed to $21.6 million for the quarter (down 35.6% year-over-year), though adjusted EBITDA loss widened slightly by 2.4%.
Management narrowed full-year 2026 revenue guidance to $142–146 million and expects adjusted gross margins to remain between 48–50%, with a projected year-end cash balance of approximately $70 million.
Strategic initiatives include the appointment of new Chief Commercial and Medical Officers, expanded insurance coverage for Alzheimer's testing in Florida, and regulatory approvals for neurology biomarker testing in China via partnership with Innovita.
The company reported no debt and a cash position of $80.7 million at quarter-end, though deferred revenue declined to $14.5 million and goodwill was reduced to zero following asset adjustments.